Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

The Quick Take
HANGZHOU, China, SHANGHAI and BOSTON, Oct. 27, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase...
Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire.



